For HER2-positive breast cancer, anti-HER2 therapy, especially dual HER2 blockade (trastuzumab and pertuzumab), has been recommended as part of the preferred neoadjuvant therapy by the NCCN (9). Here, ERBB2 is linked to breast cancer.